echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Empiric antimicrobial therapy for patients with sepsis, SWAB guideline recommendations at a glance!

    Empiric antimicrobial therapy for patients with sepsis, SWAB guideline recommendations at a glance!

    • Last Update: 2023-01-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Yimaitong compiles and arranges, please do not reprint
    without authorization.


    Sepsis is currently defined as life-threatening organ dysfunction
    resulting from an impaired host response to infection.
    Sepsis and septic shock are common causes of intensive care unit (ICU) hospitalization and are associated with
    higher mortality.
    Recently, the Dutch Antibiotic Policy Working Group (SWAB), in collaboration with relevant professional societies, updated guidelines
    for empiric antimicrobial treatment of sepsis in adults.
    The guidelines focus on the following recommendations regarding appropriate empiric antimicrobial therapy for patients with sepsis and the timing and duration of antimicrobial therapy
    .


    1.
    Empiric antibacterial therapy for sepsis


    In patients with sepsis, empiric broad-spectrum antimicrobial therapy is recommended to cover all pathogenic organisms
    that may be involved.
    (Recommended strength: strong; Quality of evidence: moderate)


    When choosing the treatment of empiric sepsis, it is recommended to consider previous (1 year) resistance in relevant clinical and screening cultures
    .
    (Recommended strength: strong; Quality of evidence: very low)


    Empiric antimicrobial therapy
    is recommended guided by the local distribution of sepsis-associated pathogens and antimicrobial susceptibility.
    (Recommended strength: strong; Quality of evidence: very low)


    When highly resistant organisms (HRMO) are likely to be involved, empiric antimicrobial therapy to cover HRMO
    is recommended in patients with sepsis.
    (Recommended strength: weak; Quality of evidence: very low)


    For patients presenting with sepsis and lower GI intra-abdominal infection or necrotizing soft-tissue infection, empiric antimicrobial therapy is recommended to cover anaerobic organisms
    .
    (Recommended strength: weak; Quality of evidence: very low)


    Conventional empiric antimicrobial therapy with antianaerobic bacteria is not recommended in patients with sepsis due to aspiration pneumonia unless empyema or lung abscess
    is suspected.
    (Recommended strength: weak; Quality of evidence: very low)


    Routine empiric treatment
    of enterococci is generally not recommended in patients presenting with sepsis.
    (Recommended strength: strong; Quality of evidence: moderate)


    Antienterococcal therapy may be considered in individual patients with sepsis, such as those with a high likelihood of enterococcal infection on recent cultures and recent complex abdominal surgery or suspected central venous catheter (CVC) infection and extensive broad-spectrum antibiotics
    .
    (Recommended strength: weak; Quality of evidence: very low)


    Routine dual-active empiric antimicrobial therapy
    is not recommended in patients with sepsis or septic shock.
    (Recommended strength: strong; Quality of evidence: moderate)


    In patients with sepsis caused by Pseudomonas aeruginosa, dual-active empiric antimicrobial therapy is not routinely definitive.

    (Recommended strength: weak; Quality of evidence: very low)


    Dual-active empiric antimicrobial therapy is not used as routine definitive therapy
    in patients with sepsis due to Staphylococcus aureus infection not related to the prosthetic material.
    (Recommended strength: weak; Quality of evidence: moderate)


    2.
    The timing and course of antibacterial treatment of sepsis


    In patients with sepsis or septic shock, immediate initiation of antimicrobial therapy is recommended, with minimal duration
    if feasible.
    (Recommended strength: strong; Quality of evidence: low)


    If possible, source control is recommended to support antimicrobial therapy
    in patients with sepsis.
    (Recommended strength: strong; Quality of evidence: low)


    4-day antimicrobial therapy
    is recommended for patients with sepsis due to intra-abdominal infection with effective source control and good clinical response.
    (Recommended strength: strong; Quality of evidence: moderate)


    In patients with sepsis and cholangitis, a shorter course of antimicrobial therapy (up to 3 days)
    is recommended after adequate biliary drainage.
    (Recommended strength: weak; Quality of evidence: very low)


    For most patients with sepsis due to ventilator-associated pneumonia (VAP), a duration of 7 days of antimicrobial therapy is sufficient
    .
    (Recommended strength: strong; Quality of evidence: moderate)


    For most patients with sepsis due to hospital-acquired pneumonia (HAP), a duration of 7 days of antimicrobial therapy is sufficient
    .
    (Recommended strength: weak; Quality of evidence: very low)


    For most patients with sepsis due to suspected central venous catheter infection with gram-negative pathogens, a maximum duration of 7 days of antimicrobial therapy after removal of the central venous catheter and a good clinical response is sufficient
    .
    (Recommended strength: weak; Quality of evidence: very low)


    For most patients with sepsis due to suspected central venous catheter infection with coagulase-negative staphylococcus (CNS) or enterococci, a duration of antimicrobial therapy of 0 to 7 days is sufficient
    after the central venous catheter has been removed and there is a good clinical response.
    (Recommended strength: weak; Statement of Good Practice)


    For most clinically responsive patients with sepsis and septic shock who do not have a clear lesion, a duration of antimicrobial therapy of 7 days is sufficient
    .
    (Recommended strength: weak; Quality of evidence: low)


    It is recommended that patients with sepsis be assessed daily for the need for antimicrobial therapy and discontinued if clinical and microbiological evidence of infection is lacking during follow-up
    .
    (Recommended strength: strong; Statement of Good Practice)


    If the optimal course of antibiotic therapy is not known, procalcitonin levels can be used to support a shorter duration
    of antimicrobial therapy in patients with sepsis.
    (Recommended strength: weak; Quality of evidence: moderate)


    Antibiotic de-escalation
    is recommended for all patients with sepsis treated daily with antibiotics based on pathogen identification, sensitivity, and risk of adverse events.
    (Recommended strength: weak; Quality of evidence: very low)


    Discontinuation of empiric aminoglycoside therapy
    is recommended within up to 2 days.
    (Recommended strength: weak; Quality of evidence: low)


    It is recommended to switch systemic antibiotic therapy from intravenous to oral after 48 to 72 hours, depending on the clinical situation and when oral
    agents are available.
    (Recommended strength: weak; Quality of evidence: very low)


    References: Sieswerda E, Bax HI, et al.
    The 2021 Dutch Working Party on Antibiotic Policy (SWAB) guidelines for empirical antibacterial therapy of sepsis in adults.
    BMC Infect Dis.
    2022 Aug 11; 22(1):687.
    doi: 10.
    1186/s12879-022-07653-3.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.